Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Macrophage deactivation by interleukin 10.

C Bogdan1, Y Vodovotz, C Nathan

  • 1Beatrice and Samuel A. Seaver Laboratory, Department of Medicine, Cornell University Medical College, New York, New York 10021.

The Journal of Experimental Medicine
|December 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Desiccation-induced DNA damage facilitates drug resistance in <i>Mycobacterium tuberculosis</i>.

bioRxiv : the preprint server for biology·2025
Same author

Cellular blue nevus tumor presenting as a submandibular lymph node in a 16-year-old.

American journal of otolaryngology·2021
Same author

Early Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tuberculosis.

Antimicrobial agents and chemotherapy·2020
Same author

A conceptual time window-based model for the early stratification of trauma patients.

Journal of internal medicine·2019
Same author

A quality improvement project to increase self-administration of medicines in an acute hospital.

International journal for quality in health care : journal of the International Society for Quality in Health Care·2018
Same author

Crossing the bridge to VATS lobectomy.

Annals of the Royal College of Surgeons of England·2017
Same journal

Retraction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.

The Journal of experimental medicine·2026
Same journal

Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models.

The Journal of experimental medicine·2026
Same journal

Flawed translation triggers oncogenic B-T cell communication.

The Journal of experimental medicine·2026
Same journal

Correction: LCK'ed in: Inborn errors of immunity in LCK reveal how TCR signaling is calibrated.

The Journal of experimental medicine·2026
Same journal

Mechanobiology of inflammation: Pulling the strings of innate immunity.

The Journal of experimental medicine·2026
Same journal

Bile acid retention in efferocytic macrophages shapes their inflammatory status during cholangitis.

The Journal of experimental medicine·2026
See all related articles

Interleukin 10 (IL-10) potently suppresses macrophage release of tumor necrosis factor alpha (TNF-alpha) and reactive oxygen intermediates (ROI). This cytokine

Area of Science:

  • Immunology
  • Cell Biology

Background:

  • Macrophages play a critical role in immune responses.
  • Interleukin 10 (IL-10) is a cytokine with known immunomodulatory functions.
  • Tumor necrosis factor alpha (TNF-alpha), reactive oxygen intermediates (ROI), and reactive nitrogen intermediates (RNI) are key macrophage-derived mediators.

Purpose of the Study:

  • To investigate the potency and specificity of recombinant mouse IL-10 on macrophage effector functions.
  • To compare the effects of IL-10 with other known macrophage suppressor cytokines.
  • To elucidate the potential implications of IL-10's effects on macrophage-mediated immunity.

Main Methods:

  • Recombinant mouse IL-10 was used to treat mouse peritoneal macrophages (m phi).
  • Macrophage release of TNF-alpha, ROI, and RNI was measured.

Related Experiment Videos

  • Inhibition concentrations (IC50) were determined for IL-10's effects.
  • Neutralizing antibodies were used to assess the independence of suppressor factors.

    • Main Results:

    • IL-10 potently suppressed TNF-alpha release (IC50 0.04 U/ml).
    • IL-10 markedly suppressed ROI release (IC50 3.7 U/ml) but weakly inhibited RNI release.
    • At higher concentrations, IL-10 deactivated macrophages, potentially impairing antimicrobial and anti-tumor functions.
    • IL-10's effects on macrophages are distinct from transforming growth factor beta and macrophage deactivation factor.

    Conclusions:

    • IL-10 significantly impacts macrophage effector functions, particularly TNF-alpha and ROI production.
    • Differential effects of IL-10 on TNF-alpha, ROI, and RNI suggest context-dependent roles in immunity.
    • IL-10's distinct mechanism of action from other suppressor cytokines highlights its unique immunomodulatory profile.
    • Macrophage deactivation by IL-10 may have implications for host defense against pathogens and tumors.